Kolkhir P.Salameh P.Zajac M.Kasperska-Zajac A.Giménez-Arnau A.Puertolas M.Bonnekoh H.Vera Ayala C.Makris M.Chatzidimitriou E.Gregoriou S.Kulthanan K.Bauer A.Bizjak-Suran M.Fomina D.Bocquet A.Dissemond J.Abuzakouk M.Raftery T.Chapman-Rothe N.Kocatürk E.Grattan C.Asero R.Peter J.G.Thomsen S.F.Weller K.Mahidol University2026-02-062026-02-062026-01-01Allergy European Journal of Allergy and Clinical Immunology (2026)01054538https://repository.li.mahidol.ac.th/handle/123456789/114658Background: Many patients with chronic spontaneous urticaria (CSU) remain symptomatic despite receiving second-generation H<inf>1</inf>-antihistamines (sgH<inf>1</inf>-AH). This data analysis from the Chronic Urticaria Registry (CURE) aimed to describe treatment patterns and identify unmet needs in real-world practice. Methods: CURE is an international, prospective registry of patients with chronic urticaria. Treatment responses were categorized as Urticaria Control Test (UCT) changes from baseline (BL) to 6-month follow-up (FU). Complete response was defined as UCT = 16 with a ≥ 3-point increase. Results: Data were available from 3995 adult patients with CSU at BL and 1288 at FU with evaluable UCT. After treatment escalation from BL to FU, 5.3% (no treatment to licensed-dose sgH<inf>1</inf>-AH), 6.0% (licensed-dose sgH<inf>1</inf>-AH to up-dosed sgH<inf>1</inf>-AH), and 28.4% (any dose sgH<inf>1</inf>-AH to omalizumab) achieved complete response. Factors associated with a lower probability of treatment escalation at FU were UCT ≥ 12 and omalizumab treatment at BL (both p < 0.0001). About one-third (28.6%) of patients clinically eligible for escalation at BL (UCT < 12) did not receive step-up treatment (18.0%) or were even stepped down (10.6%) and remained poorly controlled at FU. Factors associated with lack of escalation in this group included younger age (p = 0.014), shorter disease duration (p = 0.071), presence of wheals and angioedema (p = 0.002), better quality of life (p = 0.001), and treatment with up-dosed sgH<inf>1</inf>-AH (p = 0.031). Conclusion: Appropriate treatment escalation improves CSU control, although only about a quarter of patients achieve a complete response, indicating the need for novel treatments. Many patients with poorly controlled CSU do not receive guideline-recommended treatment escalation and remain symptomatic on their current treatments, which deserves further attention.MedicineImmunology and MicrobiologyArticleSCOPUS10.1111/all.701992-s2.0-1050275138841398999541532642